R Squared Ltd Reduces AbbVie Inc. Stake

Investment firm cuts holdings in pharmaceutical company by over 85%

Mar. 3, 2026 at 12:39am

Got story updates? Submit your updates here. ›

R Squared Ltd, an investment management firm, decreased its position in AbbVie Inc. (NYSE:ABBV) by 85.4% in the 3rd quarter, according to the company's recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 1,516 shares of the pharmaceutical company's stock, down from 10,376 shares previously.

Why it matters

AbbVie is a major pharmaceutical company with a diverse product portfolio spanning immunology, oncology, neuroscience, and other therapeutic areas. Changes in institutional ownership of the stock can signal shifts in investor sentiment and market expectations around the company's performance and outlook.

The details

According to the 13F filing, R Squared Ltd sold 8,860 shares of AbbVie stock during the 3rd quarter, reducing its total holdings to 1,516 shares valued at $351,000. The filing does not provide specific reasons for the firm's decision to significantly reduce its AbbVie position.

  • R Squared Ltd filed its 13F report for the 3rd quarter of the year.

The players

R Squared Ltd

An investment management firm that previously held a sizable position in AbbVie Inc.

AbbVie Inc.

A global biopharmaceutical company focused on developing and commercializing specialty medicines across multiple therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

The substantial reduction in R Squared Ltd's AbbVie holdings suggests the firm may have a more cautious outlook on the pharmaceutical company's prospects, though the specific reasons behind the move are unclear from the available information. Investors will likely continue to monitor changes in institutional ownership and analyst sentiment around AbbVie as it navigates its product pipeline and competitive landscape.